Sun Pharma’s brand, Brevipil (Brivaracetam) tablet 25 mg/50 mg/75 mg/100 mg February 21, 2021.
Brevipil oral solution (10 mg/ml) and injectable (10 mg/ml) will be available in the market over the next few weeks.
Brivaracetam is approved by the Drugs Controller General of India (DCGI), as an adjunctive therapy in treatment of partial-onset seizures in patients 16 years of age and older with epilepsy.
Said, Kirti Ganorkar, CEO – India Business, Sun Pharma, “We are introducing the complete range of Brivaracetam in India at a competitive pricing which will improve patient access.”
“Brivaracetam belongs to the class of anti-epileptic drugs (AEDs) which have a unique or different mechanism of action compared to the existing treatment options.
It has fast onset of action and promising efficacy.
Long-term studies indicate that the response obtained with the use of Brivaracetam is sustained, with favourable tolerability profile and compliance to the treatment,” informed the company through a statement.
While epilepsy is a common neurological disorder, because of the social stigma surrounding epilepsy, cultural practices and poor awareness of new treatment options, management of epilepsy in India continues to be a challenge.
It is estimated that around 5.7 million to 6.4 million people in India suffer from epilepsy.
BRIVIACT is a trademark of UCB.
Go to main website, click here
Subscribe for daily free updates, click here
For daily free updates on WhatsApp, click here